La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Microbot Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Microbot Medical..

Microbot Medical (NASDAQ:MBOT) Azioni, Catena delle Opzioni

Microbot Medical

Microbot Medical Inc is a clinical-stage medical device company specializing in the research, design and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is focused on leveraging its robotic technologies to redefine surgical robotics while improving surgical outcomes for patients. Using its LIBERTY technological platform, the company is developing the first-ever fully disposable robot for various endovascular interventional procedures.

Microbot Medical Inc

Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock is trading higher on Wednesday.
As per data from Benzinga Pro, session volume stands at 31.74 million versus an <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">average volume of 674.72k</a>.
What Happened: The medical device and pharmaceutical packaging company initiated shipments for previously announced purchase orders across <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45766676/sharps-technology-begins-shipments-across-three-customer-orders-under-previously-announced-purchas" rel="noreferrer noopener">three customer orders</a>.
These shipments mark the company&#8217;s first deliveries of its SecureGard and SoloGard product lines and its transition to generating commercial revenue.
&#8220;These initial shipments mark a key operational milestone as Sharps officially transitions to a commercial-stage company,&#8221; stated Robert Hayes, CEO of Sharps Technology.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39647243/whats-going-on-with-nano-cap-medical-device-focused-sharps-technology-on-friday" rel="noreferrer noopener">What&#8217;s Going On With Nano-Cap Medical Device-Focused Sharps Technology On Friday?</a>
<h1 class="wp-block-heading">SoloGard Shipment</h1>
Sharps has initiated shipment of its first commercial order of SoloGard under a previously announced $50 million supply agreement with a U.S.-based leader in <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">IV flushing solutions</a>.
The delivery includes customized 10ml SoloGard smart safety syringes manufactured at the company&#8217;s upgraded facility in Hungary.
SoloGard is a smart safety syringe featuring ultra-low waste design, standard luer lock compatibility and re-use prevention technology.
This inaugural $400,000 purchase order marks the beginning of a five-year contract to supply up to 500 million syringes and represents the first revenue-generating shipment under the strategic supply agreement.
SoloGard&#8217;s manufacturing is supported by advanced molding and automation technologies recently invested in by the company, enabling Sharps to meet the anticipated increase in demand under the agreement during the second half of 2025.
<h1 class="wp-block-heading">SecureGard Shipment</h1>
Sharps delivered SecureGard smart safety syringes in a separate shipment to a Hungarian vaccine provider following a $100,000 purchase order.
SecureGard is a safety syringe featuring an integrated active recessed safety system, ultra-low waste design and re-use prevention technology.
Combined with the SoloGard order, total purchase commitments reached approximately $500,000, establishing Sharps as a revenue-producing company and supporting its transition to commercial operations.
<h1 class="wp-block-heading">Additional Shipment</h1>
Additionally, Sharps has commenced shipment of 200,000 units of 1ml low-dead space syringes to a Swiss-based global provider of cosmetic, dental and ophthalmic injectable therapies.
The syringes will be used in a specialized injection pen to deliver Botox and represent the first tranche of a 1-million-unit order.
STSS Price Action: STSS stock is up 60.60% at $6.01 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45770679/alibaba-jd-see-sales-soar-in-618-festival-apple-and-xiaomi-emerge-as-top-selling-brands" target="_blank" rel="noreferrer noopener">Alibaba, JD See Sales Soar In 618 Festival, Apple And Xiaomi Emerge As Top Selling Brands</a></li>
</ul>
Photo: solarseven via Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

STSS

Why Is Sharps Technology Stock Soaring On Wednesday?

Cellectar Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock is trading higher on Wednesday.
As per data from Benzinga Pro, session volume stands at 361.96 million versus an <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">average volume of 968.03k</a>.
What Happened: The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation on Wednesday for the company&#8217;s iopofosine I 131, a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for relapsed/refractory Waldenstrom <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">macroglobulinemia (r/r WM)</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/12/42442003/cellectar-biosciences-stock-plunges-as-cancer-focused-cancer-firm-pursues-strategic-options" target="_blank" rel="noreferrer noopener">Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options</a>
Why It Matters: WM is the dominant subtype of lymphoplasmacytic lymphoma.
Data from the Phase 2 CLOVER WaM study, including the overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2%, which exceeded the agreed-upon primary endpoint of a 20% MRR, were presented during the 66th Annual American Society of Hematology Conference in December 2024.
As previously announced, the FDA also granted iopofosine I 131 Fast Track Designation <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45768008/cellectar-granted-u-s-fda-breakthrough-therapy-designation-for-iopofosine-i-131-in-waldenstrom-mac" rel="noreferrer noopener">and Orphan Drug Designation</a>.
The European Medicines Agency (EMA) granted Orphan Drug Designation to iopofosine I&nbsp;131 for r/r WM and PRIME Designation for WM.
What&#8217;s Next: Separately, the company has provided the EMA with a data package that includes extensive supportive preclinical, regulatory, and manufacturing data and safety and efficacy data from the CLOVER WaM Phase 2b clinical trial.
The EMA will review the package to determine whether there is enough clinical evidence to address the required criteria for Cellectar to apply for a fast-track, conditional marketing authorization approval.
In late July 2025, the company expects a recommendation from the EMA on whether Cellectar should file a Medical Authorization Application.
Price Action: CLRB stock is trading higher by 57.9% to $0.43 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/small-cap/25/06/45770622/sprinklr-rises-on-solid-earnings-raised-outlook-and-new-150-million-buyback-plan" target="_blank" rel="noreferrer noopener">Sprinklr Rises On Solid Earnings, Raised Outlook, And New $150 Million Buyback Plan</a></li>
</ul>
Photo by Tada Images via Shutterstock

News

CLRB

What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained

WIIM

ONEOK shares are trading lower after the company acquired the remaining shares of Basin JV for $940 million. Additionally, Barclays cut its price target on the stock from $101 to $91.

<a href="https://www.bloomberg.com/news/articles/2025-06-04/trump-tariffs-carney-holds-back-on-retaliation-says-us-talks-are-progressing">https://www.bloomberg.com/news/articles/2025-06-04/trump-tariffs-carney-holds-back-on-retaliation-says-us-talks-are-progressing</a>

'Carney Holds Back on Tariff Retaliation, Says US-Canada Talks Are Progressing'- Bloomberg

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 5.23% on an annualized basis producing an average annual return of 17.22%. Currently, Verisk Analytics has a market capitalization of $44.41 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $1,103.04 today based on a price of $317.51 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749054696_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

Here's How Much You Would Have Made Owning Verisk Analytics Stock In The Last 15 Years

HOTH

Hoth Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 25%

Acting FAA Administrator Rocheleau Reportedly Says He is Not Currently Thinking About Revisiting Boeing's 38 Plane Per Month 737 Max Production Cap

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1535527/000153552725000019/crwd-20250430.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1535527/000153552725000019/crwd-20250430.htm</a>

CRWD

Crowdstrike Has Received Requests From DOJ, SEC for Information Relating to the Company's Recognition of Revenue and Reporting of ARR for Transactions With Certain Customers, the July 19 Incident and Related Matters

Thor Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) shares are trading higher on Wednesday after the company reported third-quarter EPS of $2.53 <a href="https://www.benzinga.com/earnings">beating the street consensus of $1.83</a>.
Quarterly sales of&nbsp;$2.89 billion, up 3.3%&nbsp;year over year (Y/Y), outpaced the analyst <a href="https://www.benzinga.com/pressreleases/25/06/g45766242/thor-industries-announces-third-quarter-fiscal-2025-results" target="_blank" rel="noreferrer noopener">consensus estimate of&nbsp;$2.48 billion</a>.
Gross profit margin in the quarter under review expanded by 20 basis points year over year to&nbsp;15.3%.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a>
Adjusted EBITDA increased 7.9%&nbsp;Y/Y to&nbsp;$254.8 million in the quarter.
North American Towable Recreational Vehicle (RV) net sales increased&nbsp;9.1% Y/Y, while North American Motorized RV net sales rose 3.1%&nbsp;Y/Y in the quarter.
North American Towable RV net sales benefitted from 5.5% higher unit shipments and a 3.6% increase in net price per unit. 
Gross profit margin improved 200 basis points to 14.9%, attributed to higher sales, less discounting, better warranty costs, and ongoing savings.
North American Motorized RV net sales increased due to a 10.9% rise in unit shipments (partly from promotions), though a 7.8% decrease in net price per unit (due to product mix shift and higher discounting) partially offset this. 
Gross profit margin fell to 10.5% from 11.1%, primarily owing to increased sales discounting.
As of April 30, the order backlog for North American Towable RV stood at $634.3 million (-14.4%) and North American Motorized RV came in at $883.7 million (-4.5%).
European RV net sales decreased&nbsp;5.1% Y/Y&nbsp;for the&nbsp;quarter, led by a&nbsp;12.2%&nbsp;decrease in unit shipments, which was offset in part by a&nbsp;7.1% Y/Y&nbsp;increase in the overall net price per unit.&nbsp;
European RV net sales fell due to a 12.2% drop in unit shipments, partially offset by a 7.1% increase in net price per unit. The price increase included a 6.8% rise from product mix and pricing changes, plus a 0.3% benefit from foreign currency exchange rates.
European RV gross profit margin contracted 130 basis points to 16.2% on increased sales discounting.
As of&nbsp;April 30, the order backlog for European RV came in at $1.34 billion (-30.6%).
The company exited the quarter with cash and cash equivalents worth&nbsp;$508.3 million, with net inventories worth&nbsp;$1.35 billion. Long-term debt (net) at the end of the quarter stood at $1.01 billion.
Todd Woelfer, senior VP and COO, said, &#8221;As we anticipated and messaged at the beginning of our fiscal year, our North American Motorized and European segments have both seen year-over-year declines in gross margin but still achieved resilient results considering the challenging environments facing those segments.&#8221; 
&#8221;While our consolidated margin this quarter was unfavorably impacted by actions we took to deepen our partnerships with key dealers, strategically, deepening these key relationships is vital to our long-term market position and these decisions favorably position THOR for the future as we look ahead,&#8221;
Thor Industries reaffirmed its FY25 EPS guidance of $3.30 to $4.00 compared <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">to analyst estimates of $3.59</a>.
The company also maintained its FY25 sales guidance at $9.00 billion to $9.50 billion versus the <a target="_blank" href="https://www.benzinga.com//node/44139488" rel="noreferrer noopener">analyst estimate of $9.25 billion</a>.
Bob Martin, president and CEO, added, &#8221;Our financial guidance assumed a stronger second half of our fiscal year, and our fiscal third quarter performance reflects the value of our strategies in the currently difficult market.&#8221;
&#8221;We expect the fourth quarter of our fiscal 2025 and the first quarter of our fiscal 2026 to be challenging. The current economic uncertainty has led to downward pressure on consumer confidence and has negatively impacted retail pull-through. We believe that upon the resolution of this uncertainty, we will see improved consumer confidence and the return of a strong retail environment,&#8221; he added.
Year-to-date, the stock has declined around 11%. The short float for Thor Industries is 18.33%, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Price Action: THO shares are trading higher by 3.44% to $85.25 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45765484/dow-futures-edge-higher-after-two-days-of-gains-expert-says-trump-tariffs-distorting-pretty-much-everything" target="_blank" rel="noreferrer noopener">Dow Futures Edge Higher After Two Days Of Gains: Expert Says Trump Tariffs &#8216;Distorting Pretty Much Everything&#8217;</a></li>
</ul>
Image by Michael Gordon via Shutterstock

Earnings

Guidance

Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook

Analyst Ratings

MSFT

Live On CNBC, Jim Lebenthal Announced Trimmed Microsoft

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang highlighted the company's role in helping boost the new features of <a href="https://www.benzinga.com/general/gaming/25/04/44609298/nintendo-switch-2-price-release-date-specs-new-games-revealed">the highly anticipated</a><a href="https://www.benzinga.com/general/gaming/25/04/44609298/nintendo-switch-2-price-release-date-specs-new-games-revealed"> </a>Nintendo Switch 2 gaming console from Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) in a recent video.
What Happened: Nintendo stock has soared in 2025 ahead of the June 5 release of the Switch 2, a handheld video game console that follows up the highly successful Nintendo Switch released in 2017.
"It brings together three breakthroughs: the most advanced graphics ever in a mobile device, full hardware ray tracing, high dynamic range for brighter highlights and deeper shadows and an architecture that supports backward compatibility," Huang said in a video <a href="https://x.com/NintendoAmerica/status/1929886108113932624">shared </a>by Nintendo.
Huang said the Nvidia chip inside the Switch 2 is "unlike anything we've built before," as <a href="https://www.cnbc.com/amp/2025/06/03/nintendo-switch-2-ai-nvidia.html">reported</a> by CNBC.
The Nvidia CEO said the Switch 2 has dedicated artificial intelligence processors that will help to "sharpen, animate and enhance gameplay in real time."
"Switch 2 is more than a new console. It's a new chapter worthy of Iwata-san's vision."
Huang's comments paid tribute to former Nintendo CEO Satoru Iwata, who passed away in 2015 before the first Switch was released. Iwata worked on the concept of the original Switch.
Read Also:<a href="https://www.benzinga.com/news/education/25/05/45701924/jensen-huang-founded-nvidia-at-a-dennys-now-hes-worth-600x-more-than-the-restaurant-chain"> Jensen Huang Founded Nvidia At A Denny&#8217;s, Now He&#8217;s Worth 600x More Than The Restaurant Chain</a>
Why It's Important: The Nintendo Switch 2 will be released on June 5 and comes with a suggested retail price of $449.99 for the U.S. market.
The console is the first from Nintendo in eight years and comes with new features that have gamers excited to get their hands on devices as soon as possible.
Nintendo expects to sell 15 million Switch 2 consoles in the current fiscal year, as <a href="https://www.cnbc.com/video/2025/05/08/nintendo-expects-to-sell-15-million-units-of-the-switch-2.html">reported </a>by CNBC. The console will likely help boost Nintendo's financials and could send shares higher with strong early sales figures and high demand.
Nvidia stock could also get a small boost. While the Gaming &amp; AI PC division for Nvidia is smaller than its Data Center business, the segment saw first-quarter revenue of $3.8 billion, which was up 42% year-over-year.
The gaming segment saw revenue jump 48% quarter-over-quarter in the first quarter, the highest sequential growth of any Nvidia segment.
Nvidia highlighted its products being used for the Nintendo Switch 2 during the earnings report. The big question will be how much of the revenue is already baked into the segment versus potential upside from more devices sold in future quarters or demand quickly outpacing supply.
Price Action: Nvidia stock is down 0.24% at $140.89 on Wednesday versus a 52-week trading range of $86.63 to $153.13. Nvidia stock is up 2.1% year-to-date in 2025.
Nintendo stock is up 2.40% at $20.93 on Wednesday versus a 52-week trading range of $11.36 to $22.08. Nintendo stock is up 42.9% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong">Nvidia Q1 Highlights: China Export Ban Hits Results But Jensen Huang Says Demand &#8216;Incredibly Strong&#8217;</a></li>
</ul>
Photo: Shutterstock

Gaming

Long Ideas

Management

Tech

NTDOY

NVDA

Jensen Huang Says Nintendo Switch 2 Has AI Processors To Enhance Gameplay: 'Unlike Anything We've Built Before'

JPMorgan analyst Mark R Murphy <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings" target="_blank" rel="noreferrer noopener">reiterated an Overweight</a> rating on Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a price target of $225 on Wednesday.
Murphy attended Snowflake&#8217;s Investor Day presentation in San Francisco, in conjunction with its annual Summit conference. Snowflake&#8217;s Investor Day presentation primarily focuses on its product and technology roadmap as it lays out an expansive strategic vision for the data cloud in the era of AI, the analyst said.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45623498/snowflakes-ai-driven-insights-to-power-la28-olympic-and-paralympic-games" rel="noreferrer noopener">Snowflake&#8217;s AI-Driven Insights To Power LA28 Olympic And Paralympic Games</a>
A financial section was absent from the Investor Day presentation, an understandable dynamic as Snowflake continues its process to select a new CFO after current CFO Mike Scarpelli&#8216;s planned retirement, he said.
Despite the lack of explicit financial guidance or macro-demand update, Murphy noted Snowflake is striking a confident tone overall as it begins to realize benefits from the product, go-to-market (GTM), and other operational initiatives it has undertaken or accelerated since Sridhar Ramaswamy was elevated to CEO in February 2024.
Net-net, the analyst came away incrementally positive following the Investor Day and the relatively upbeat nature of his conversations thus far with partners and customers regarding Snowflake.
Recently-appointed CRO Mike Gannon provided an overview of Snowflake&#8217;s Go-To-Market organization and stated that Snowflake hired over 500 sales and marketing folks in the first quarter. While the 500 additional S&amp;M heads is a gross figure, Murphy noted the hiring scale is notable, particularly as hiring activity across many other software companies has been relatively more muted, and likely reflects the opportunity Snowflake is seeing in the market.
Snowflake discussed ongoing industry adoption of the Iceberg data formats, noting that open data table formats like Iceberg make it easier for customers to switch between different data processing engines. As a result, the analyst noted that Snowflake said that customers will move toward the data platforms that offer the most value.
For Snowflake, Iceberg is experiencing a dynamic wherein the tailwinds and opportunity it provides &#8220;far exceed and outpace the potential headwinds,&#8221; he said.
When asked about its view on more and more SaaS companies moving into the data layer, Murphy said that Snowflake suggested that this move is driven by AI as the rise of Agents is potentially impacting the traditional SaaS model.
However, Snowflake noted that it has a bidirectional data-sharing dynamic with many leading SaaS companies and that the relationships are mutually beneficial.
Snowflake built on its vision of the AI Data Cloud through a series of product unveilings. These announcements included Openflow, Gen2, Adaptive Compute, Intelligence, Snowflake Data Science Agent, and Cortex AISQL.
Murphy is encouraged by Snowflake&#8217;s slate of new products and the recent increased pace of innovation.
In the long term, the analyst noted that Snowflake is benefiting from demonstrable secular tailwinds, supported both qualitatively and quantitatively by his CIO Survey and partner checks. He continues to be impressed by the company&#8217;s accelerated pace of product innovation, including around AI/ML. 
Murphy noted favorable competitive positioning in the longer term as the data layer increasingly gains control over AI.
The analyst projected second-quarter revenue of $1.08 billion and adjusted EPS of $0.25.
Price Action: SNOW stock is trading higher by 1% to $211.24 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45755544/rising-ai-analytics-budgets-could-lift-microsoft-snowflake-datadog" target="_blank" rel="noreferrer noopener">Rising AI, Analytics Budgets Could Lift Microsoft, Snowflake, Datadog</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

SNOW

Snowflake Just Hired 500 Sellers—Is This The Start Of A Full-Scale AI Land Grab?

CSCO

QCOM

Live On CNBC, Jim Lebenthal Announced Bought More Cisco; Bought More Qualcomm

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 5 years by 16.18% on an annualized basis producing an average annual return of 29.4%. Currently, Amphenol has a market capitalization of $111.72 billion. 
Buying $100 In APH: If an investor had bought $100 of APH stock 5 years ago, it would be worth $354.53 today based on a price of $92.25 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749053712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Amphenol 5 Years Ago Would Be Worth This Much Today

On June 3, 2025 Enterprise Products Partners Received Notice From The U.S. Department Of Commerce's Bureau Of Industry And Security Of BIS's Intent To Deny Emergency Authorization Requests With Regard To Three Proposed Cargoes Of Ethane To China, Totaling Approximately 2.2M Barrels

The Magnificent Seven did not disappoint in May, posting a <a href="https://www.benzinga.com/etfs/new-etfs/25/06/45722678/magnificent-seven-closed-a-blockbuster-may-added-nearly-2-trillion-in-market-value">record-breaking $1.75 trillion in collective market cap gain</a>, their strongest combined performance in years. 
The center of the mania: the Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>), which saw its best monthly performance since inception, powered by an AI-driven, earnings-supported technology surge.
But with valuations sky-high and Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in reverse gear, is this still a time to buy, or has the market become too magnificent for its own good?
Benzinga spoke to David Mazza, <a href="https://www.benzinga.com/topic/david-mazza">CEO of Roundhill Investments</a>, to discuss the factors behind MAGS&#8217; &#8220;best month since inception&#8221; and whether the <a href="https://www.benzinga.com/etfs">ETF&#8217;s star status</a> still shines through in changing macro winds.
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/45774924/apple-stock-too-pricey-analyst-warns-of-rising-competition-tariff-risks-favors-2-tech-giants">Apple Stock Too Pricey? Analyst Warns Of Rising Competition, Tariff Risks, Favors 2 Tech Giants</a>
<h2 class="wp-block-heading">Broad-Based Gains, Not Just A One-Stock Show</h2>
&#8220;What stood out was the breadth of the rally,&#8221; Mazza said in an interview with Benzinga. &#8220;Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) led with a 24% gain, but Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) also posted double-digit gains, signaling a broad-based resurgence in the mega caps.&#8221;
The tailwind, Mazza said, was fueled by easing trade tensions and healthy earnings, especially in AI and cloud. &#8220;While we anticipated strength from these companies, the magnitude and breadth of the rally exceeded expectations.&#8221;
Nvidia contributed alone with $639 billion worth of market cap, while Tesla and Meta were not far behind. Microsoft added $484 billion, Amazon increased by $219 billion, and Alphabet added $152 billion.
Also Read:<a href="https://www.benzinga.com/etfs/new-etfs/25/06/45774136/wedbush-launches-ai-revolution-etf-backed-by-dan-ives-proprietary-tech-picks"> Wedbush Launches AI Revolution ETF Backed By Dan Ives&#8217; Proprietary Tech Picks</a>
<h2 class="wp-block-heading">Apple Lags Behind, But MAGS Remains Firm</h2>
The sole laggard among the gang was Apple, which dropped 6%, erasing $192 billion in market capitalization and significantly underperforming the S&amp;P 500. Nevertheless, MAGS&#8217; equal-weighting approach prevented the decline from derailing the ETF&#8217;s performance.
&#8220;Apple&#8217;s underperformance, influenced by trade tensions and delayed AI initiatives, presents a potential buying opportunity,&#8221; Mazza said, highlighting the stock&#8217;s solid ecosystem and diversified manufacturing strategy.
<h2 class="wp-block-heading">Why The Magnificent Seven Still Matter</h2>
More than mere tech giants, Mazza views the Magnificent Seven as critical plumbing to the economy of today. These firms drive everything from cloud computing to e-commerce, he said. &#8220;MAGS focuses exclusively on these companies, providing targeted exposure to the core drivers of modern economic growth.&#8221;
As opposed to the broad tech ETFs that encompass legacy or cyclical names, MAGS is laser-like. And while volatility clouds traditional sectors, some analysts, including Goldman Sachs, have referred to these mega-caps as a &#8220;defensive growth proxy.&#8221;
Mazza does too.
&#8220;These companies combine strong growth prospects with resilient business models, making them attractive during uncertain times. Goldman Sachs&#8217; characterization of them as a &#8216;defensive growth proxy&#8217; aligns with our view,&#8221; he agreed.
<h2 class="wp-block-heading">The Question Of Valuation: Bubble Or Justified?</h2>
With the Magnificent Seven's forward P/E ratio now pushing 27.4x, the ghost of the dot-com bubble inevitably enters the chat. But Mazza sees a key difference.
"While the group&#8217;s median forward P/E ratio has risen to around 27x, it&#8217;s important to note that these valuations are supported by substantial earnings growth and strong fundamentals," he said. "Unlike the dot-com era, these companies are profitable and generate significant cash flow," Mazza noted. Nvidia, for example, posted a 69% YoY revenue jump last quarter.
<h2 class="wp-block-heading">Earnings Outlook And The AI Edge</h2>
Mazza is also optimistic about earnings, citing the group&#8217;s leading position in AI, cloud, and digital services. &#8220;Given their central roles in AI, cloud computing, and digital services, we anticipate continued earnings momentum as demand for these technologies persists and expands across various sectors.&#8221;
While MAGS provides exposure to high-cap AI adopters, Roundhill also has the CHAT ETF available for investors wanting more focused plays on Generative AI.
&#8220;We view AI as a transformative force with long-term implications. The companies within MAGS are not only early adopters, but also key enablers of AI technologies,&#8221; Mazza clarified. 
<h2 class="wp-block-heading">What&#8217;s Next For MAGS?</h2>
Even with the monster rally, Mazza dampens expectations for the remainder of 2025.
&#8220;We don't expect a repeat of the massive gains we saw in the past year, but that doesn't mean the story is over,&#8221; he conceded. &#8220;If earnings growth remains solid and rate expectations stay in check, MAGS could still deliver compelling returns, just more measured than the blockbuster runs we&#8217;ve recently witnessed.&#8221;
With the market still characterized by uncertainty, Mazza feels that Magnificent Seven&#8217;s growth, quality, and macro sensitivity are an elusive combination.
These companies are essential to enterprise and consumer activity,&#8221; he said. &#8220;And MAGS is built to give investors direct exposure to that durability.&#8221;
<h2 class="wp-block-heading">Bottom Line</h2>
May might have been magnificent, but the future of MAGS will be more measured, not muted. For those who want a high-conviction wager on AI, cloud, and the core players in the digital economy, Mazza makes the case the ETF is a singularly focused yet compelling entry point.
After all, in a world short on clarity, the Magnificent Seven might just be the market&#8217;s most down-to-earth stars.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45771855/vistashares-unleashes-wild-a-2x-leveraged-etf-powered-by-animal-spirits-and-market-momentum">VistaShares Unleashes WILD, A 2x Leveraged ETF Powered By Animal Spirits And Market Momentum</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

Exclusives

ETFs

AAPL

AMZN

GOOGL

MAGS

TSLA

David Mazza On MAGS' Magnificent May: 'The Breadth Of The Rally Stood Out'

Loop Capital analyst Mark Schappel maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $220 to $245.

Loop Capital Maintains Buy on Snowflake, Raises Price Target to $245

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) re-elected all current directors on Wednesday. The board authorized the payment of a cash dividend of $2.21 per share, up from the <a href="https://www.unitedhealthgroup.com/investors/stock.html" target="_blank" rel="noopener">prior</a> dividend of $2.10, to be paid June 24 to common stock shareholders of record as of the close of <a href="https://www.benzinga.com/pressreleases/25/06/b45766386/unitedhealth-group-updates-on-annual-shareholder-meeting-board-actions" target="_blank" rel="noreferrer noopener">business June 16</a>.
In May, UnitedHealth Group&#8217;s CEO&nbsp;, Andrew Witty,&nbsp;resigned for personal reasons. Stephen Hemsley, who previously held the CEO title from 2006 to 2017,&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">succeeded him</a>. The company also suspended its 2025 outlook.
In an SEC filing on Wednesday, UnitedHealth <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/731766/000073176625000154/unh-20250602.htm" target="_blank" rel="noreferrer noopener">said</a> it canceled the performance-based restricted stock units granted to Witty,
Year to date, UnitedHealth Group&#8217;s stock has plunged almost 40%, with the majority coming after the disappointing fourth-<a href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" target="_blank" rel="noreferrer noopener">quarter 2024 earnings</a>.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45687019/unh-stock-broken-contrarian-traders-eyeball-recovery" target="_blank" rel="noreferrer noopener">Options Corner: UnitedHealth May Be Broken But Contrarian Traders Eyeball A Recovery</a>
UnitedHealth&#8217;s aggressive growth strategy under Witty exposed the healthcare giant to mounting regulatory scrutiny, soaring costs, and a <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">shifting Medicare landscape</a>.
UnitedHealth plans to enlist independent experts to examine its Medicare billing practices, which were criticized following a Wall Street Journal <a href="https://www.benzinga.com/general/health-care/25/05/45443695/why-is-unitedhealth-stock-trading-lower-on-thursday" target="_blank" rel="noreferrer noopener">investigation last year</a>.
Hemsley is stepping forward to acknowledge the fallout and chart a new course, promising a comprehensive review of some of the company's most controversial practices.
The Wall Street Journal noted in its report on the company's annual shareholder meeting on Monday that Hemsley apologized for UnitedHealth's recent performance and cited a need to rethink many internal processes.
He said the company has factored recent results into its 2025 Medicare bids and emphasized a "fresh perspective" on issues that have drawn widespread criticism.
Under Witty, UnitedHealth scaled up its dominance in Medicare Advantage, the privately managed alternative to traditional Medicare.
Former employees said UnitedHealth's profit margins on Medicare enrollees were roughly double those of traditional Medicare insurers.
That advantage stemmed partly from federal rules that limit the premium revenue pure insurers can keep. Additionally, the government pays more for patients with certain chronic diagnoses—a system UnitedHealth capitalized on by gathering such data at high rates.
However, changes announced by the Medicare agency in 2023 altered the rules, reducing or eliminating extra payments for many diagnoses. The changes, phased in starting this year, were expected to have a major financial impact.
An internal analysis <a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-ceo-andrew-witty-medicare-dde1964c" rel="noreferrer noopener">viewed</a> by the WSJ indicated the new rules would significantly reduce the number of reimbursable chronic diagnoses for nearly 900,000 patients.
Despite this, UnitedHealth continued betting on Medicare growth for 2025, even in high-risk patient segments, while rivals pulled back following profit hits in 2024 tied to rising costs.
Hemsley said the company would also examine its pharmacy services and managed care policies, including prior authorization—a process that has faced growing criticism from physicians and patients.
Price Action: UNH stock was flat at $301.29 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" target="_blank" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a></li>
</ul>
Photo: Piotr Swat / Shutterstock.com

Large Cap

Dividends

UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices

Truist Securities analyst Scot Ciccarelli maintains Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Hold and raises the price target from $93 to $112.

Truist Securities Maintains Hold on Dollar General, Raises Price Target to $112

Truist Securities analyst Joel Fishbein reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $450 to $500.

Truist Securities Reiterates Buy on CrowdStrike Holdings, Raises Price Target to $500

Press Releases

Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®

Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting

Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Financing

Microbot Medical Closes $13 Million Registered Direct Offering

Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting

Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System

REMINDER: Microbot Medical Announces Data from the Company's ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting

Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System

Global Robotic Exoskeleton Market Size Expected to Reach $30 Billion By 2032 as A.I. Influence Disrupts the Industry

Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers

CHRW

KULR

MBOT

Apyx Medical

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

CytoSorbents

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Edap TMS

Fonar

Fractyl Health

Kewaunee Scientific Corporation - Common Stock

Kewaunee Scientific

KORU Medical Systems, Inc. - Common Stock

KORU Medical Systems

LENSAR

Lucid Diagnostics

Pulmonx

Monogram Technologies Inc. - Common Stock

Monogram Technologies

Milestone Scientific

Myomo

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Hldgs

Odysight ai

Owlet

Pro-Dex

Sensus Healthcare

Vivani Medical

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International

Zynex

HC Wainwright & Co.

Screenshot 2024-12-13 at 6.45.20 PM

Advanced Robotics Are Reshaping Medicine

Untitled design - 2024-12-10T185819.364

Movers & Shakers

ISRG

Palm-Sized Innovation: How Microbot Medical Is Helping Redefine Surgical Robotics

Comments

Microbot Medical

Microbot Medical (MBOT) Opzioni

Microbot Medical (NASDAQ:MBOT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO